

Appendix Table 1 – Outcome of fieldwork: ascertainment and interviewing by country

a) Meningioma cases

| Data collection outcome | Overall | | Country | | | | | | | | | | | | UK | |
|---|-----------------|----|-----------|----------|----------|----------|------------|-----------|-----------|-----------|------------|-------------|------------|----------|-----------|----------|
| | Number of cases | % | Australia | Canada | Denmark | Finland | France | Germany | Israel | Italy | Japan | New Zealand | Norway | Sweden | North | South |
| | | | | | | | | | | | | | | | | |
| Number of cases ascertained | 3115 | | 413 | 134 | 155 | 252 | 190 | 275 | 390 | 124 | 102 | 72 | 191 | 205 | 222 | 390 |
| Outcome of attempt to interview | | | | | | | | | | | | | | | | |
| % refused | 339 | 11 | 17 | 13 | 14 | 7 | 9 | 3 | 8 | 8 | 5 | 15 | 1 | 6 | 10 | 24 |
| % MD refused | 69 | 2 | 4 | 7 | 0 | 0 | 5 | 0 | 0 | 1 | 15 | 3 | 0 | 2 | 0 | 3 |
| % died or too ill | 66 | 2 | 1 | 2 | 6 | 0 | 2 | 4 | 1 | 2 | 0 | 3 | 0 | 2 | 4 | 4 |
| % untraced or other reasons ¹ | 216 | 7 | 16 | 7 | 0 | 2 | 8 | 3 | 1 | 0 | 0 | 7 | 22 | 0 | 5 | 13 |
| % interviewed | 2425 | 78 | 62 | 70 | 81 | 92 | 76 | 91 | 90 | 89 | 80 | 72 | 77 | 90 | 81 | 56 |
| Interview | | | | | | | | | | | | | | | | |
| % self respondent | 2383 | 98 | 100 | 96 | 98 | 99 | 99 | 98 | 97 | 92 | 100 | 98 | 99 | 98 | 99 | 100 |
| % face-to-face | 2294 | 95 | 100 | 100 | 100 | 99 | 95 | 100 | 100 | 65 | 100 | 100 | 53 | 93 | 100 | 100 |
| Delay between diagnosis and interview ² (months) | | | | | | | | | | | | | | | | |
| median | 3.4 | | 3.9 | 7.7 | 3.2 | 1.3 | 3.4 | 0.0 | 4.1 | 8.2 | 1.8 | 4.1 | 15.4 | 5.7 | 2.3 | 5.6 |
| 5-95 percentiles | 0.0/21.9 | | 1.4/17.7 | 2.5/22.9 | 0.8/13.7 | 0.0/8.4 | 0.2/27.9 | -0.4/9.5 | 0.2/24.2 | 0.9/19.7 | 0.4/12.8 | 1.8/9.0 | -0.1/29.9 | 0.3/15.7 | 1.0/11.4 | 1.8/23.9 |
| Delay between case and control interviews ³ (months) | | | | | | | | | | | | | | | | |
| median | -2.1 | | -0.3 | -0.3 | -0.5 | -0.5 | -4.1 | -3.1 | -9.3 | -3.2 | -5.1 | -4.1 | -0.4 | -0.5 | -2.9 | 0.0 |
| 5-95 percentiles | -16.1/6.3 | | -9.2/10.6 | -3.6/7.8 | -5.2/2.0 | -6.2/2.0 | -14.1/-0.8 | -11.1/6.5 | -33.0/6.5 | -15.0/5.5 | -14.4/-1.3 | -29.2/11.7 | -14.9/11.4 | -8.1/6.6 | -9.4/-0.9 | -8.4/8.7 |

¹ This includes 7 cases who were interviewed but for whom data were lost (these are included as non-interviewed subjects in the current paper, unlike in Cardis et al 2007 (26)).

² Date of interview – date of diagnosis

³ Date of case interview – date of control interview

b) Glioma cases

| Data collection outcome | Overall | | Country | | | | | | | | | | | | | |
|--|-----------------|-----|--------------|------------|------------|------------|--------------|--------------|-------------|--------------|--------------|-------------|--------------|-------------|--------------|-------------|
| | Number of cases | % | Australia | Canada | Denmark | Finland | France | Germany | Israel | Italy | Japan | New Zealand | Norway | Sweden | UK | |
| | | | | | | | | | | | | | | | North | South |
| Number of cases ascertained | 4301 | 100 | 536 | 273 | 248 | 211 | 155 | 312 | 206 | 128 | 90 | 132 | 236 | 298 | 628 | 848 |
| Outcome of attempt to interview | | | | | | | | | | | | | | | | |
| % refused | 470 | 11 | 16 | 7 | 16 | 12 | 19 | 5 | 6 | 1 | 4 | 10 | 1 | 8 | 10 | 15 |
| % MD refused | 198 | 5 | 4 | 7 | 0 | 0 | 7 | 0 | 0 | 1 | 26 | 4 | 0 | 9 | 2 | 8 |
| % died or too ill | 637 | 15 | 14 | 18 | 10 | 1 | 6 | 11 | 6 | 6 | 3 | 14 | 0 | 5 | 16 | 33 |
| % untraced or other reasons ² | 231 | 5 | 9 | 6 | 1 | 2 | 6 | 1 | 0 | 0 | 0 | 9 | 22 | 1 | 3 | 7 |
| % interviewed | 2765 | 64 | 56 | 62 | 73 | 84 | 61 | 82 | 87 | 92 | 67 | 64 | 76 | 76 | 68 | 36 |
| Interview | | | | | | | | | | | | | | | | |
| % self respondent | 2416 | 87 | 86 | 82 | 94 | 97 | 89 | 90 | 81 | 56 | 98 | 80 | 69 | 93 | 92 | 95 |
| % face-to-face | 2606 | 94 | 99 | 97 | 100 | 99 | 97 | 100 | 99 | 61 | 100 | 100 | 52 | 94 | 100 | 100 |
| Delay between diagnosis and interview (months) | | | | | | | | | | | | | | | | |
| median | 2.9 | | 3.5 | 6.1 | 2.2 | 0.5 | 1.9 | 0.1 | 3.5 | 6.2 | 1.4 | 3.8 | 15.0 | 2.7 | 2.1 | 4.4 |
| 5-95 percentiles | 0.0 / 18.8 | | 1.3 / 18.8 | 2.9 / 12.2 | 0.5 / 11.2 | 0.0 / 5.0 | 0.3 / 24.1 | -0.3 / 15.1 | 0.2 / 20.6 | 0.4 / 17.5 | 0.3 / 6.5 | 1.8 / 8.5 | -0.1 / 33.2 | 0.5 / 12.4 | 1.0 / 8.5 | 1.4 / 19.8 |
| Delay between case and control interviews (months) | | | | | | | | | | | | | | | | |
| median | -2.3 | | -0.5 | -1.2 | -0.5 | -0.9 | -4.5 | -3.0 | -8.1 | -4.6 | -6.0 | -4.6 | 0.1 | -1.2 | -2.9 | -0.6 |
| 5-95 percentiles | -13.9 / 7.1 | | -11.2 / 10.8 | -8.6 / 5.8 | -7.2 / 2.2 | -7.8 / 2.1 | -11.4 / -0.9 | -11.6 / 13.0 | -32.8 / 4.0 | -17.2 / 13.5 | -16.3 / -1.3 | -38.3 / 3.0 | -10.9 / 17.0 | -12.0 / 3.6 | -10.4 / -0.9 | -13.5 / 7.4 |

²This includes 12 cases who were interviewed but for whom data were lost (these are included as non-interviewed subjects in the current paper, unlike in Cardis et al 2007 (26))

Brain tumour risk in relation to mobile telephone use: results of the INTERPHONE international case-control study – IJE, May 2010

c) Controls (all)

| Data collection outcome | Overall | | Country | | | | | | | | | | | | | |
|--|--------------------|----|-----------|--------|---------|---------|--------|---------|--------|-------|-------|-------------|--------|--------|-------|-------|
| | Number of controls | % | Australia | Canada | Denmark | Finland | France | Germany | Israel | Italy | Japan | New Zealand | Norway | Sweden | UK | |
| | | | | | | | | | | | | | | | North | South |
| Number of controls sampled | 14354 | | 1608 | 1330 | 1277 | 1337 | 639 | 1869 | 911 | 486 | 568 | 350 | 404 | 617 | 1747 | 1211 |
| Outcome of attempt to interview | | | | | | | | | | | | | | | | |
| % refused | 4303 | 30 | 37 | 32 | 32 | 42 | 21 | 29 | 25 | 13 | 25 | 16 | 21 | 22 | 20 | 47 |
| % MD refused | 126 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7 | 0 |
| % died or too ill | 49 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| % untraced or other reasons ¹ | 2218 | 15 | 21 | 18 | 16 | 16 | 5 | 6 | 9 | 17 | 25 | 35 | 10 | 12 | 27 | 5 |
| % interviewed | 7658 | 53 | 42 | 49 | 52 | 42 | 74 | 64 | 66 | 70 | 51 | 49 | 69 | 66 | 45 | 48 |
| Interview | | | | | | | | | | | | | | | | |
| % self respondent | 7615 | 99 | 100 | 99 | 100 | 100 | 100 | 100 | 100 | 95 | 100 | 88 | 100 | 100 | 100 | 100 |
| % face-to-face | 7179 | 94 | 98 | 98 | 100 | 99 | 88 | 100 | 99 | 35 | 100 | 100 | 54 | 94 | 100 | 100 |

¹This includes 38 controls who were interviewed but for whom data were lost

Appendix Table 2 – ORs between mobile phone use and brain tumours (meningioma and glioma separately) using the “Inskip method” for comparing side of use with side of tumour, by different windows of time before the reference date – excludes use with hands-free devices

a) Meningioma

| Time window/ Side of use | Overall | | | | Highest decile of cumulative call time only | | | | |
|--|-----------------------|------------------------|-----------------|-----------|---|------------------------|-----------------|-----------|--|
| | Left sided tumours | Right sided tumours | OR ¹ | 95% CI | Left sided tumours | Right sided tumours | OR ¹ | 95% CI | |
| Overall | | | | | | | | | |
| Left | 185 | 153 | 1.00 | | 21 | 13 | 1.00 | | |
| Right | 255 | 278 | 1.07 | 1.00 1.16 | 25 | 32 | 1.22 | 0.96 1.62 | |
| Regular users 1-4 years before reference date | | | | | | | | | |
| Left | 111 | 86 | 1.00 | | 5 | 2 | 1.00 | | |
| Right | 147 | 163 | 1.10 | 1.00 1.22 | 3 | 5 | 1.52 | 0.81 3.88 | |
| Regular users 5-9 years before reference date | | | | | | | | | |
| Left | 58 | 54 | 1.00 | | 8 | 9 | 1.00 | | |
| Right | 91 | 86 | 1.00 | 0.90 1.14 | 15 | 15 | 0.97 | 0.76 1.36 | |
| Regular users 10 years or more before reference date | | | | | | | | | |
| Left | 16 | 13 | 1.00 | | 8 | 2 | 1.00 | | |
| Right | 17 | 29 | 1.22 | 0.95 1.68 | 7 | 12 | 1.81 | 0.98 4.09 | |

b) Glioma

| Time window/ Side of use | Overall | | | | Highest decile of cumulative call time only | | | | |
|--|-----------------------|------------------------|-----------------|-----------|---|------------------------|-----------------|-----------|--|
| | Left sided tumours | Right sided tumours | OR ¹ | 95% CI | Left sided tumours | Right sided tumours | OR ¹ | 95% CI | |
| Overall | | | | | | | | | |
| Left | 281 | 170 | 1.00 | | 48 | 20 | 1.00 | | |
| Right | 345 | 499 | 1.27 | 1.19 1.37 | 37 | 68 | 1.55 | 1.24 1.99 | |
| Regular users 1-4 years before reference date | | | | | | | | | |
| Left | 125 | 86 | 1.00 | | 8 | 1 | 1.00 | | |
| Right | 167 | 247 | 1.23 | 1.12 1.37 | 4 | 7 | 2.37 | 0.93 8.59 | |
| Regular users 5-9 years before reference date | | | | | | | | | |
| Left | 116 | 54 | 1.00 | | 21 | 9 | 1.00 | | |
| Right | 128 | 169 | 1.34 | 1.19 1.53 | 18 | 25 | 1.40 | 1.04 2.01 | |
| Regular users 10 years or more before reference date | | | | | | | | | |
| Left | 40 | 30 | 1.00 | | 19 | 10 | 1.00 | | |
| Right | 50 | 83 | 1.24 | 1.05 1.50 | 15 | 36 | 1.57 | 1.13 2.30 | |

¹ ORs adjusted for sex, age, study centre, ethnicity in Israel, and education.

Appendix Table 3 – ORs between mobile phone use and brain tumours (meningioma and glioma separately); joint analyses of effects of phone technology (analogue and digital) and phone use – excludes use with hands-free devices

| Type of phone signal | Exposure category | Meningioma | | | | | Glioma | | | | |
|----------------------|--|------------|----------|-----------------|--------|------|--------|----------|-----------------|--------|------|
| | | Cases | Controls | OR ¹ | 95% CI | | Cases | Controls | OR ¹ | 95% CI | |
| Analogue | Never regular user or non analogue user | 2182 | 2392 | 1.00 | | | 2283 | 2518 | 1.00 | | |
| | Ever regular analogue user | 227 | 270 | 0.81 | 0.65 | 1.03 | 425 | 454 | 1.00 | 0.83 | 1.21 |
| | Cumulative call time (hours) of exclusive analogue use | | | | | | | | | | |
| | <5 hours | 14 | 21 | 0.63 | 0.29 | 1.37 | 30 | 26 | 1.34 | 0.66 | 2.72 |
| | 5 h - 114.9 | 84 | 111 | 0.72 | 0.51 | 1.01 | 161 | 188 | 0.92 | 0.70 | 1.22 |
| | 115-359.9 | 59 | 55 | 1.13 | 0.71 | 1.80 | 85 | 103 | 0.93 | 0.65 | 1.33 |
| | 360-1639.9 | 48 | 49 | 0.84 | 0.51 | 1.39 | 91 | 108 | 0.86 | 0.60 | 1.24 |
| | 1640 + | 22 | 34 | 0.50 | 0.25 | 0.99 | 58 | 29 | 1.95 | 1.08 | 3.54 |
| Digital | Never regular user or non digital user | 1266 | 1306 | 1.00 | | | 1252 | 1276 | 1.00 | | |
| | Ever regular digital user | 1143 | 1356 | 0.79 | 0.68 | 0.92 | 1456 | 1696 | 0.76 | 0.66 | 0.88 |
| | Cumulative call time (hours) of exclusive digital use | | | | | | | | | | |
| | <5 hours | 160 | 209 | 0.86 | 0.65 | 1.12 | 156 | 202 | 0.69 | 0.52 | 0.92 |
| | 5 h - 114.9 | 511 | 642 | 0.72 | 0.60 | 0.86 | 639 | 764 | 0.80 | 0.68 | 0.96 |
| | 115-359.9 | 194 | 259 | 0.81 | 0.63 | 1.05 | 266 | 332 | 0.71 | 0.56 | 0.89 |
| | 360-1639.9 | 182 | 189 | 0.80 | 0.60 | 1.06 | 267 | 320 | 0.65 | 0.51 | 0.83 |
| | 1640 + | 96 | 57 | 1.84 | 1.17 | 2.88 | 128 | 78 | 1.46 | 0.98 | 2.17 |
| Unknown or both | Never regular user or only analogue or only digital user | 2174 | 2395 | 1.00 | | | 2292 | 2574 | 1.00 | | |
| | Ever regular user of unknown signal type or both analogue and digital phones | 235 | 267 | 1.05 | 0.84 | 1.32 | 416 | 398 | 1.13 | 0.93 | 1.38 |
| | Cumulative call time (hours) of exclusive unknown or both use | | | | | | | | | | |
| | <5 hours | 27 | 30 | 1.19 | 0.64 | 2.22 | 30 | 36 | 1.10 | 0.60 | 2.02 |
| | 5 h - 114.9 | 106 | 124 | 1.08 | 0.78 | 1.51 | 177 | 179 | 1.03 | 0.78 | 1.35 |
| | 115-359.9 | 40 | 54 | 0.81 | 0.49 | 1.34 | 88 | 82 | 1.12 | 0.76 | 1.66 |
| | 360-1639.9 | 44 | 49 | 0.95 | 0.56 | 1.61 | 81 | 74 | 1.46 | 0.95 | 2.26 |
| | 1640 + | 18 | 10 | 4.43 | 1.42 | 13.9 | 40 | 27 | 1.37 | 0.69 | 2.70 |

¹ ORs adjusted for sex, age, study centre, ethnicity in Israel, and education.

Appendix Table 4 – Results of additional sensitivity analyses on ORs between mobile phone use and brain tumours (meningioma and glioma separately) for the highest decile of cumulative call time, covering method of analysis, adjustment for confounders and influence of individual study centres

| | Meningioma | | | | | Glioma | | | | |
|--|-----------------|----------|-----------------|---------|------|--------|----------|-----------------|---------|------|
| | Cases | Controls | OR ¹ | 95 % CI | | Cases | Controls | OR ¹ | 95 % CI | |
| Main analysis (baseline for comparison) | 130 | 107 | 1.15 | 0.81 | 1.62 | 210 | 154 | 1.40 | 1.03 | 1.89 |
| Method of analysis | | | | | | | | | | |
| Stratified analysis | 130 | 107 | 1.10 | 0.82 | 1.48 | 207 | 154 | 1.39 | 1.08 | 1.77 |
| Adjustment for confounders | | | | | | | | | | |
| Epilepsy | 130 | 107 | 1.16 | 0.82 | 1.63 | 210 | 154 | 1.44 | 1.07 | 1.96 |
| Skull x-rays 5 years prior to reference date | 130 | 107 | 1.17 | 0.83 | 1.66 | 210 | 154 | 1.49 | 1.09 | 2.03 |
| Neck x-rays 5 years prior to reference date | na ² | | | | | 210 | 154 | 1.43 | 1.05 | 1.94 |
| Full mouth x-rays 2 years prior to reference date | na | | | | | 210 | 154 | 1.40 | 1.03 | 1.90 |
| Regular smoking | na | | | | | 210 | 154 | 1.41 | 1.04 | 1.90 |
| Industrial work involving heating of food or other materials | na | | | | | 210 | 154 | 1.42 | 1.04 | 1.92 |
| Working with electrical motors | na | | | | | 210 | 154 | 1.39 | 1.03 | 1.88 |
| Working with ionising radiation | na | | | | | 210 | 154 | 1.41 | 1.04 | 1.91 |
| Use of portable or non-portable transmitters | 130 | 107 | 1.18 | 0.83 | 1.66 | 210 | 154 | 1.44 | 1.06 | 1.95 |
| Impact of individual countries | | | | | | | | | | |
| Exclude Australia | 114 | 95 | 1.16 | 0.80 | 1.69 | 176 | 132 | 1.39 | 0.99 | 1.95 |
| Exclude Canada | 125 | 101 | 1.15 | 0.81 | 1.64 | 196 | 147 | 1.41 | 1.03 | 1.93 |
| Exclude Denmark | 125 | 106 | 1.07 | 0.76 | 1.52 | 201 | 147 | 1.40 | 1.02 | 1.92 |
| Exclude Finland | 103 | 88 | 1.13 | 0.77 | 1.66 | 182 | 135 | 1.34 | 0.97 | 1.85 |
| Exclude France | 126 | 102 | 1.13 | 0.80 | 1.60 | 202 | 151 | 1.38 | 1.02 | 1.88 |
| Excluding Germany | 126 | 98 | 1.17 | 0.81 | 1.67 | 202 | 146 | 1.35 | 0.98 | 1.85 |
| Excluding Israel | 109 | 76 | 1.30 | 0.90 | 1.88 | 196 | 130 | 1.47 | 1.08 | 2.02 |
| Excluding Italy | 122 | 104 | 1.08 | 0.76 | 1.54 | 205 | 151 | 1.40 | 1.03 | 1.90 |
| Excluding Japan | 127 | 104 | 1.15 | 0.81 | 1.62 | 204 | 150 | 1.40 | 1.03 | 1.90 |
| Excluding New Zealand | 127 | 107 | 1.14 | 0.81 | 1.62 | 202 | 148 | 1.39 | 1.02 | 1.89 |
| Excluding Norway | 122 | 105 | 1.08 | 0.76 | 1.54 | 197 | 149 | 1.38 | 1.01 | 1.89 |
| Excluding Sweden | 124 | 99 | 1.28 | 0.89 | 1.84 | 198 | 148 | 1.36 | 0.99 | 1.85 |
| Excluding UK-North | 123 | 106 | 1.15 | 0.81 | 1.62 | 185 | 135 | 1.42 | 1.05 | 1.93 |
| Excluding UK-South | 117 | 100 | 1.12 | 0.78 | 1.62 | 184 | 133 | 1.46 | 1.04 | 2.03 |

¹ ORs adjusted for sex, age, study centre, ethnicity in Israel, and education.

² na: this factor was not related to mobile phone use in controls or to risk of disease in non mobile phone users and was therefore not considered as a potential confounder for meningioma

Appendix Table 5 – Results of sensitivity analyses on ORs between mobile phone use and brain tumours (meningioma and glioma separately) for regular use, covering possible indicators of sample representativeness and response quality

| Factors included in sensitivity analyses | Meningioma | | | | | Glioma | | | | |
|---|------------|----------|-----------------|---------|------|--------|----------|-----------------|---------|------|
| | Cases | Controls | OR ¹ | 95 % CI | | Cases | Controls | OR ¹ | 95 % CI | |
| Main analysis (baseline for comparison) | 1262 | 1488 | 0.79 | 0.68 | 0.91 | 1666 | 1894 | 0.81 | 0.70 | 0.94 |
| Presentation of the study | | | | | | | | | | |
| Explicit mention of mobile phones | 634 | 737 | 0.67 | 0.55 | 0.82 | 827 | 878 | 0.87 | 0.71 | 1.07 |
| Mobile phones mentioned, but not stressed | 502 | 619 | 0.86 | 0.68 | 1.08 | 710 | 888 | 0.72 | 0.57 | 0.91 |
| No mention of mobile phones | 126 | 132 | 1.54 | 0.74 | 3.23 | 129 | 128 | 0.85 | 0.46 | 1.58 |
| Participation rates | | | | | | | | | | |
| Study centres with control participation rates < 60% | 634 | 692 | 0.78 | 0.63 | 0.97 | 1015 | 1062 | 0.91 | 0.74 | 1.12 |
| Study centres with control participation rates ≥ 60% | 628 | 796 | 0.79 | 0.64 | 0.96 | 651 | 832 | 0.70 | 0.56 | 0.86 |
| Excluding study centres with hospital based case ascertainment ² | 1175 | 1395 | 0.79 | 0.68 | 0.91 | 1584 | 1815 | 0.81 | 0.69 | 0.94 |
| Quality and timing of interview | | | | | | | | | | |
| Excluding proxy interviews | 1241 | 1462 | 0.79 | 0.68 | 0.92 | 1480 | 1666 | 0.84 | 0.71 | 0.99 |
| Excluding telephone interviews | 1128 | 1351 | 0.77 | 0.65 | 0.89 | 1509 | 1737 | 0.82 | 0.70 | 0.96 |
| With experienced interviewers only ³ | 1190 | 1388 | 0.77 | 0.66 | 0.90 | 1551 | 1751 | 0.82 | 0.70 | 0.96 |
| Balanced interviewer workload ⁴ | 984 | 1138 | 0.78 | 0.66 | 0.93 | 1321 | 1490 | 0.79 | 0.66 | 0.93 |
| Control interviews within 1 month of case interview | 321 | 360 | 0.74 | 0.56 | 0.97 | 375 | 393 | 0.84 | 0.63 | 1.11 |
| Interviewer judgement of quality of response ⁵ | | | | | | | | | | |
| Excluding non-responsive study subjects or subjects with poor memory | 952 | 1141 | 0.79 | 0.67 | 0.93 | 1117 | 1282 | 0.81 | 0.67 | 0.97 |
| Duration of call time | | | | | | | | | | |
| When answered by day/week/month | 84 | 84 | 1.29 | 0.84 | 1.99 | 83 | 95 | 0.84 | 0.48 | 1.47 |
| When answered by call | 1054 | 1273 | 0.73 | 0.63 | 0.86 | 1304 | 1527 | 0.77 | 0.66 | 0.91 |
| Exclusion of subjects who reported more than 5 hours per day ⁶ | 1221 | 1452 | 0.78 | 0.67 | 0.90 | 1611 | 1844 | 0.80 | 0.69 | 0.93 |
| Use of imputation and ranges | | | | | | | | | | |
| Excluding responses with imputed items | 1082 | 1298 | 0.77 | 0.66 | 0.90 | 1301 | 1555 | 0.73 | 0.63 | 0.86 |
| Using minimum rather than median when range given | 1260 | 1483 | 0.79 | 0.69 | 0.92 | 1659 | 1889 | 0.80 | 0.69 | 0.93 |

¹ ORs adjusted for sex, age, study centre, ethnicity in Israel, and education.

² Japan and France-Paris excluded

³ Included only interviewers who conducted at least 20 interviews

⁴ Included only interviewers' whose case/control interview ratio was between 1/4 and 3/4 (between 1/6 and 5/6 in Germany where 2 controls were matched to each case)

⁵ Restricted to study subjects who the interviewers judged to be fairly or very cooperative and responsive and who were judged to remember fairly well, well or very well both their current and past mobile phone use history.

⁶ Exclusion was based on all use of a mobile phone; that is, including use with hands-free devices

Appendix Table 6 – Distribution of Regular User OR for meningioma and glioma by ratio of case to control participation rates

| | Meningioma | | | | Glioma | | | |
|-------------|------------------------|----------|--------------------|--|------------------------|----------|--------------------|--|
| | Participation rate (%) | | | OR ² for regular use 1 year or more in the past | Participation rate (%) | | | OR ² for regular use 1 year or more in the past |
| | Cases | Controls | Ratio ¹ | | Cases | Controls | Ratio ¹ | |
| Australia | 62 | 42 | 1.48 | 0.71 | 56 | 42 | 1.33 | 1.05 |
| Canada | 70 | 49 | 1.43 | 2.03 | 62 | 49 | 1.27 | 0.74 |
| Denmark | 81 | 52 | 1.56 | 1.10 | 73 | 52 | 1.40 | 0.8 |
| Finland | 92 | 42 | 2.19 | 0.68 | 84 | 42 | 2.00 | 0.85 |
| France | 76 | 74 | 1.03 | 0.77 | 61 | 74 | 0.82 | 1.00 |
| Germany | 91 | 64 | 1.42 | 1.04 | 82 | 64 | 1.28 | 0.83 |
| Israel | 90 | 66 | 1.36 | 0.50 | 87 | 66 | 1.32 | 0.96 |
| Italy | 89 | 70 | 1.27 | 1.02 | 92 | 70 | 1.31 | 0.62 |
| Japan | 80 | 51 | 1.57 | 0.91 | 67 | 51 | 1.31 | 0.58 |
| New Zealand | 72 | 49 | 1.47 | 0.65 | 64 | 49 | 1.31 | 1.12 |
| Norway | 77 | 69 | 1.12 | 0.80 | 76 | 69 | 1.10 | 0.39 |
| Sweden | 90 | 66 | 1.36 | 0.48 | 76 | 66 | 1.15 | 0.74 |
| UK North | 81 | 45 | 1.80 | 0.67 | 68 | 45 | 1.51 | 0.66 |
| UK South | 56 | 48 | 1.17 | 0.71 | 36 | 48 | 0.75 | 0.80 |

¹ Ratio of case to control participation rates

² ORs adjusted for sex, age, study centre, ethnicity in Israel, and education.